This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Villani, M. G. Articles by Formelli, F. Search for Related Content PubMed PubMed Citation Articles by Villani, M. G. Articles by Formelli, F.

4-Oxo-Fenretinide, a Recently Identified Fenretinide Metabolite, Induces Marked G₂-M Cell Cycle Arrest and Apoptosis in Fenretinide-Sensitive and Fenretinide-Resistant Cell Lines

¹ Chemoprevention Unit, Department of Experimental Oncology, Istituto Nazionale Tumori and ² Center of Excellence on Neurodegenerative Diseases, Study Center for the Biochemistry and Biotechnology of Glycolipids, Department of Medical Chemistry, Biochemistry, and Biotechnology, University of Milan, Milan, Italy; ³ Biochemistry and Pharmacy Science Division, University of Wisconsin, Madison, Wisconsin; and ⁴ Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, Ohio

Requests for reprints: Franca Formelli, Istituto Nazionale Tumori, via Venezian 1, 20133 Milan, Italy. Phone: 39-02-2390-2706; Fax: 39-02-2390-2692; E-mail: franca.formelli{at}istitutotumori.mi.it.

4-Oxo-N-(4-hydroxyphenyl)retinamide (4-oxo-4-HPR) is a recently identified metabolite of fenretinide (4-HPR). We explored the effectiveness of 4-oxo-4-HPR in inducing cell growth inhibition in ovarian, breast, and neuroblastoma tumor cell lines; moreover, we investigated the molecular events mediating this effect in two ovarian carcinoma cell lines, one sensitive (A2780) and one resistant (A2780/HPR) to 4-HPR. 4-Oxo-4-HPR was two to four times more effective than 4-HPR in most cell lines, was effective in both 4-HPR–sensitive and 4-HPR–resistant cells, and, in combination with 4-HPR, caused a synergistic effect. The tumor growth-inhibitory effects of 4-oxo-4-HPR seem to be independent of nuclear retinoid receptors (RAR), as indicated by the failure of RAR antagonists to inhibit its effects and by its poor ability to bind and transactivate RARs. Unlike 4-HPR, which only slightly affected the G₁ phase of the cell cycle, 4-oxo-4-HPR caused a marked accumulation of cells in G₂-M. This effect was associated with a reduction in the expression of regulatory proteins of G₂-M (cyclin-dependent kinase 1 and cdc25c) and S (cyclin A) phases, and with an increase in the expression of apoptosis-related proteins, such as p53 and p21. Apoptosis was induced by 4-oxo-4-HPR in both 4-HPR–sensitive and 4-HPR–resistant cells and involved activation of caspase-3 and caspase-9 but not caspase-8. We also showed that 4-oxo-4-HPR, similarly to 4-HPR, increased reactive oxygen species generation and ceramide levels by de novo synthesis. In conclusion, 4-oxo-4-HPR is an effective 4-HPR metabolite that might act as therapeutic agent per se and, when combined with 4-HPR, might improve 4-HPR activity or overcome 4-HPR resistance. (Cancer Res 2006; 66(6): 3238-47)